Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent.
Wang P, Li X, Wang J, Gao D, Li Y, Li H, Chu Y, Zhang Z, Liu H, Jiang G, Cheng Z, Wang S, Dong J, Feng B, Chard LS, Lemoine NR, Wang Y.
Wang P, et al. Among authors: feng b.
Nat Commun. 2017 Nov 9;8(1):1395. doi: 10.1038/s41467-017-01385-8.
Nat Commun. 2017.
PMID: 29123084
Free PMC article.